145 withdrawn. 145 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 145 | Withdrawn 145 |
Follow Infections: new trials by email Literature Review of Infections trials Research Report on Infections
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Shingrix in Patients With Rheumatic Diseases: a Double-blind Placebo-controlled RCT recombinant subunit herpes zoster vaccine - Herpes Zoster | Phase 4 | Withdrawn | Tuen Mun Hospital | 2026-09-29 | 2026-10-01 | |
| Efficacy of Topical Apraclonidine for the Treatment of Ocular Synkinesis Apraclonidine - Synkinesis, Facial Nerve Palsy | Phase 4 | Withdrawn | University of Alabama at Birmingham | 2025-12-01 | 2024-07-19 | |
| Trachoma Elimination Study by Focused Antibiotic (TESFA) Azithromycin mass treatment, Azithromycin targeted treatment - Trachoma | Phase 4 | Withdrawn | Emory University | 2025-06-01 | 2025-07-16 | |
| Botulinum Toxin-A for Hidradenitis Suppurativa Normal saline, Botulinum toxin type A - Hidradenitis Suppurativa, Hidradenitis Suppurativa \(HS\) | Phase 4 | Withdrawn | Yale University | 2025-01-01 | 2025-12-16 | |
| Azithromycin Reduction to Reach Elimination of Trachoma B Azithromycin - Trachoma | Phase 4 | Withdrawn | University of California, San Francisco | 2024-10-01 | 2026-03-13 | |
| Prophylactic Antibiotics for Surgical Site Infections and Beta-Lactam Allergy cephalosporin, Second tier antibiotic (Vancomycin) - Surgical Site Infection, Beta-lactam Allergy | Phase 4 | Withdrawn | University of Texas Southwestern Medical Center | 2024-08-16 | 2023-12-15 | |
| Open-label Trial to Evaluate Efficacy and Safety of rhNGF on Corneal Thickness Via AS-OCT in Neurotrophic Keratitis OXERVATE® 0.002% - Neurotrophic Keratitis, Neurotrophic Keratopathy | Phase 4 | Withdrawn | Dompé Farmaceutici S.p.A | 2024-04-26 | 2024-12-02 | |
| Tetrandrine Tablets Used in Hospitalized Adults With COVID-19 Tetrandrine - COVID-19 | Phase 4 | Withdrawn | Peking University Third Hospital | 2023-12-31 | 2024-10-01 | |
| Tafenoquine and Primaquine in Colostrum and Breast Milk Primaquine, Tafenoquine - Healthy Lactating Women | Phase 4 | Withdrawn | University of Oxford | 2023-07-01 | 2024-04-04 | |
| Dalbavancin Outpatient Pilot Dalbavancin - Gram-Positive Bacterial Infections, Soft Tissue Infections | Phase 4 | Withdrawn | Wake Forest University Health Sciences | 2023-04-01 | 2023-05-03 | |
| Valproate Alone or in Combination With Quetiapine for Severe COVID-19 Pneumonia With Agitated Delirium Valproate, Quetiapine, Standard of Care - Covid19, Hyperactive Delirium | Phase 4 | Withdrawn | University of Miami | 2023-03-28 | 2023-03-31 | |
| Role of Prophylactic Postoperative Antibiotics in HoLEP Nitrofurantoin, Cephalexin, Sulfamethoxazole Trimethoprim Combination - Benign Prostatic Hyperplasia, Urinary Tract Infections | Phase 4 | Withdrawn | Baylor Research Institute | 2023-03-01 | 2026-02-12 | |
| PipEracillin/Tazobactam Versus mERoPENem for Treatment of AmpC Producing Blood Stream Infections Piperacillin / Tazobactam Injection, Meropenem - Beta Lactam Resistant Bacterial Infection, Enterobacteriaceae Infections | Phase 4 | Withdrawn | Rambam Health Care Campus | 2022-07-01 | 2025-07-24 | |
| Angiotensin II vs. Vasopressin in Septic Shock Angiotensin II, Vasopressin - Septic Shock | Phase 4 | Withdrawn | University of New Mexico | 2022-01-03 | 2024-03-15 | |
| Bezlotoxumab Versus FMT for Multiple Recurrent CDI Bezlotoxumab, Fecal Microbiota Transplantation (FMT), Vancomycin oral - Clostridium Infections, Clostridioides Difficile | Phase 4 | Withdrawn | Leiden University Medical Center | 2022-01-01 | 2023-03-28 | |
| Mobile Health Interventions for Medication Adherence Among PLWH Varenicline, Mobile phone application, Contingency management - HIV/AIDS, Smoking | Phase 4 | Withdrawn | Duke University | 2021-11-01 | 2021-09-05 | |
| Elimination of HCV Through Linkage and In Prison Treatment of Incarcerated Populations (ECLIPSE) Glecaprevir/pibrentasvir - HCV Infection | Phase 4 | Withdrawn | University of Maryland, Baltimore | 2021-10-01 | 2021-05-06 | |
| Introduction of mTor Inhibitors and the Activation of the Cytomegalovirus (CMV) -Specific Cellular Immune Response Switch from Mycophenolate Mofetil to Everolimus manteinance treatment in Active Comparator Arm, no intervention - Kidney Transplantation, Cytomegalovirus Infections | Phase 4 | Withdrawn | Edoardo Melilli | 2021-09-01 | 2024-02-28 | |
| Assessing Parenteral Antibiotics Versus Single-time Intra-operative Intra-dermal Antibiotic Administration for Prevention of SSI Ceftriaxone Sodium - Surgical Wound Infection, Surgical Site Infection | Phase 4 | Withdrawn | The Grant Medical College & Sir J.J. Group of Hospitals | 2021-08-01 | 2025-03-25 | |
| Cetirizine and Famotidine for COVID-19 Cetirizine and Famotidine, Placebo - Covid19 | Phase 4 | Withdrawn | Emory University | 2021-08-01 | 2021-08-20 |
Showing 20 of 145. Sign in to see all of them.
Hepatitis C (20) · COVID-19 (13) · Acquired Immunodeficiency Syndrome (9) · Urinary Tract Infections (9) · Surgical Wound Infection (6) · Hepatitis B, Chronic (5) · Hepatitis C, Chronic (5) · Clostridium Infections (4) · HIV Infections (4) · Hepatitis B (4) · Influenza, Human (4) · Kidney Failure, Chronic (4) · Malaria (4) · Pneumonia (4)
Virus Diseases (65) · RNA Virus Infections (56) · Pathological Conditions, Signs and Symptoms (50) · Pathologic Processes (44) · Blood-Borne Infections (41) · Communicable Diseases (41) · Digestive System Diseases (35) · Hepatitis, Viral, Human (32) · Liver Diseases (32) · Respiratory Tract Diseases (32) · Bacterial Infections and Mycoses (31) · Hepatitis (31) · Urogenital Diseases (31) · Respiratory Tract Infections (30)
Azithromycin (7) · elbasvir-grazoprevir drug combination (6) · Sofosbuvir (5) · Ribavirin (4) · Albendazole (3) · Cefazolin (3) · Cephalexin (3) · Ciprofloxacin (3) · Clindamycin (3) · Hydroxychloroquine (3) · Prednisone (3) · Telbivudine (3) · Trimethoprim, Sulfamethoxazole Drug Combination (3) · glecaprevir and pibrentasvir (3) · Adrenal Cortex Hormones (2)
University of California, San Francisco (6) · Massachusetts General Hospital (5) · Emory University (4) · GlaxoSmithKline (4) · University of California, Los Angeles (4) · Merck Sharp & Dohme LLC (3) · Stanford University (3) · University of Maryland, Baltimore (3) · Wake Forest University Health Sciences (3) · Baylor Research Institute (2) · Epicentre (2) · Hoffmann-La Roche (2) · Kirby Institute (2) · McMaster University (2) · Novartis Pharmaceuticals (2)
United States (46) · Canada (5) · Australia (3) · Denmark (3) · France (3) · United Kingdom (3) · China (2) · Egypt (2) · Germany (2) · Israel (2) · Niger (2) · Spain (2) · Vietnam (2) · Belgium (1) · Brazil (1)
Raymond Chung, MD (2) · Raymond T Chung, MD (2) · Abdulhadi Quadri, MD (1) · Adaira Landry, B.A. (1) · Afsoon Roberts, M.D. (1) · Ahmed Nasr (1) · Alaa Atamna, MD (1) · Allison J McGeer, MD MSc (1) · Amy D Klion, M.D. (1) · Amy Justice, MD, PhD (1)
PMID 10321661, PMID 10697064, PMID 10923728, PMID 11555797, PMID 12186604, PMID 12487041, PMID 16444180, PMID 18090011, PMID 18826731, PMID 19388915, PMID 20600032, PMID 21063553, PMID 21197290, PMID 27266697, PMID 2803357, PMID 29600824, PMID 3029157, PMID 32178593, PMID 32224164, PMID 33027187, PMID 3306374, PMID 34645381, PMID 36041061, PMID 4101232, PMID 6270176, PMID 6384785, PMID 7600840, PMID 7634816, PMID 7638758, PMID 7862469, PMID 8815944, PMID 8855809, PMID 9491040, PMID 9559600
2009 (2), 2008 (1), 2017 (1), 5UG1EY030833 (1), K01DA043413 (1), R01AI048789 (1), R37HL068546 (1), U19AI057229 (1), U54CK000162 (1), UL1TR001449 (1)